PRESS RELEASE
14 July 2020

Now Facilities Can Access Cutting-Edge Neuro MR Capabilities to Comply with New COVID-19 Recommendations

A recent recommendation for COVID-19 patients to undergo a neuro MR exam prompted SyntheticMR to make its leading software available to institutions for better patient monitoring.

SyntheticMR announced today that their novel MR quantification solution, SyMRI NEURO, will be available for qualifying institutions who wish to scan COVID-19 patients before discharge. The move is in direct response to a recent Johns Hopkins University study that recommends patients undergo neuro MR to help physicians track patients over time.

“There’s no doubt that COVID-19 has impacted all of us in significant ways,” explains Kyle Frye, President of SyntheticMR North America. “While physicians are doing their part to care for patients, we thought it only right for us to do our part where we can. In this case, it means assisting physicians in giving access to a fast scan that delivers multiple outputs for the best possible diagnosis.”

While most are aware of respiratory affects, COVID-19 patients are also at risk for long-term neuropsychiatric and neurocognitive conditions, including depression, OCD, psychosis, Parkinson’s, and Alzheimer’s. A baseline MRI exam is critical to understanding and promoting continued care in patients. In addition, neurological complications can occur after COVID-19 infection, but it’s still not clear if this is from the virus, the body’s response, or the formation of clots.

“The last thing any doctor or patient want is another lengthy procedure when they’re trying to discharge,” continues Frye. “Our SyMRI software is a natural solution, providing a quick 5-6-minute scan that delivers 8 different contrast-weighted images that are fully adjustable for any combination of TE, TR, and T1; which means patient call back can be reduced.”

The software also provides segmentation and volume estimation of different tissue types (CSF, GM, Myelin, and WM).
“Our goal is simple: we want to provide the best solutions to doctors so they can do their job in saving lives,” adds Frye. “That’s never changed. But if we can help remove some obstacles for patients and radiologists and help foster understanding, we all win.”

For more information on how physicians and/or facilities can qualify for access to SyMRI software, please contact (859) 512-9496 or info.us@syntheticmr.com

###

About SyMRI NEURO

**SyMRI NEURO**, which is FDA cleared for patients of all ages, combines an MR sequence with post-processing MR software, and includes multiple contrast-weighted images, fully adjustable for TE, TR, and T1 values for optimal flexibility. The software includes automatic segmentations and volume measurements of tissue such as white matter, gray matter, cerebrospinal fluid and myelin to allow users to track disease progression or compare against control groups. Using a single 5-6-minute scan with a post-processing time of less than 10 seconds, SyMRI NEURO is available both as a stand-alone solution or be fully integrated into the clinical workflow.

About SyntheticMR

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from one 6-minute scan. The SyMRI product is available in different packagers. SyMRI IMAGE provides fast MRI workflows, allowing high-patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI is a CE-marked and FDA 510(k) cleared product. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden.